Sofosbuvir-ribavirin duo for chronic hepatitis c

Connecticut Medicine

Volumn 78, Issue 6, 2014, Pages 355-356

  Njei, Basile ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG COMBINATION; RIBAVIRIN; SOFOSBUVIR; URIDINE PHOSPHATE;

ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; META ANALYSIS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG COMBINATIONS; DRUG SYNERGISM; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84904342841     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335-74.
2. Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P.Treatment failure with new hepatitis C dmgs. Expert Opin Pharmacother. 2012;13:313-23.
3. FDA Antiviral Drugs Advisory Committee Meeting, October 25, 2013. FDA Web site, http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/antiviraldmgsadvisorycommitteeAicm371876.pdf. Accessed November 25, 2013.
4. Stuart A, Ord JK. Kendall's Advanced Theory of Statistics. 6th ed. London: Edward Arnold; 1994.
5. Der Simonian R, Laird N. Meta- Analysis in clinical trials. Controlled Clin Trials. 1986;7:177-88.
6. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta- Analyses of controlled trials with binary endpoints. Stat Med. 2005;25:3443-57. (Pubitemid 44575162)
7. Lalezari JP, Nelson DR, Hyland RH, et al. Once daily sofos- buvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with hCV infection: The Quantum study. J Hepatol. 2013;58:S236.
8. Gane EJ, Stedman CA, Hyland RH, et al. All-oral sofosbuvir- based 12-week regimens for the treatment of chronic HCV infection: The Electron study. J Hepatol. 2013;58:S6.
9. Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial .JAMA. 2013 Nov 13;310(18):1987.
10. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87.
11. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16;368(20):1867-77.